Jul 01, 2018 Proceedings: AACR Annual Meeting 2018; April 1418, 2018; Chicago, IL Background The androgen receptor (AR) is emerging as a potential biomarker of breast cancer prognosis and therapeutic target. AR is expressed in 6080 of breast cancers, with higher prevalence among estrogen receptor (ER) positive tumors.